These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 30341636)
21. Fracture outcomes related to persistence and compliance with oral bisphosphonates. Gallagher AM; Rietbrock S; Olson M; van Staa TP J Bone Miner Res; 2008 Oct; 23(10):1569-75. PubMed ID: 18505366 [TBL] [Abstract][Full Text] [Related]
22. Risk factors for fracture among current, persistent users of bisphosphonates. LeBlanc ES; Rosales AG; Balasubramanian A; O'Malley CD; Egbuna O; Friess D; Perrin NA Osteoporos Int; 2015 Feb; 26(2):713-25. PubMed ID: 25354654 [TBL] [Abstract][Full Text] [Related]
23. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis. Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417 [TBL] [Abstract][Full Text] [Related]
24. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study. Gonnelli S; Caffarelli C; Letizia Mauro G; Di Munno O; Malavolta N; Migliaccio S; Nuti R Aging Clin Exp Res; 2019 Nov; 31(11):1541-1547. PubMed ID: 31030419 [TBL] [Abstract][Full Text] [Related]
25. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. Park-Wyllie LY; Mamdani MM; Juurlink DN; Hawker GA; Gunraj N; Austin PC; Whelan DB; Weiler PJ; Laupacis A JAMA; 2011 Feb; 305(8):783-9. PubMed ID: 21343577 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of teriparatide in bisphosphonate-pretreated and treatment-naive patients with osteoporosis at high risk of fracture: Post hoc analysis of a prospective observational study. Yoshiki F; Nishikawa A; Taketsuna M; Kajimoto K; Enomoto H J Orthop Sci; 2017 Mar; 22(2):330-338. PubMed ID: 28038880 [TBL] [Abstract][Full Text] [Related]
27. Association between proton pump inhibitor use and risk of fracture: A population-based case-control study. Kim JJ; Jang EJ; Park J; Sohn HS PLoS One; 2020; 15(7):e0235163. PubMed ID: 32730257 [TBL] [Abstract][Full Text] [Related]
29. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures . Meijer WM; Penning-van Beest FJ; Olson M; Herings RM Curr Med Res Opin; 2008 Nov; 24(11):3217-22. PubMed ID: 18922215 [TBL] [Abstract][Full Text] [Related]
30. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Solomon DH; Hochberg MC; Mogun H; Schneeweiss S Osteoporos Int; 2009 Jun; 20(6):895-901. PubMed ID: 18843515 [TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness and safety outcomes between denosumab and bisphosphonate in South Korea. Park C; Kim C; Park RW; Jeon JY J Bone Miner Res; 2024 Aug; 39(7):835-843. PubMed ID: 38722817 [TBL] [Abstract][Full Text] [Related]
33. Bisphosphonate Use and Hospitalization for Hip Fractures in Women: An Observational Population-Based Study in France. Bourrion B; Souty C; Fournier L; Vilcu AM; Blanchon T; Böelle PY; Hanslik T; François M Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444529 [TBL] [Abstract][Full Text] [Related]
34. Incidence of second hip fracture and compliant use of bisphosphonate. Lee YK; Ha YC; Yoon BH; Koo KH Osteoporos Int; 2013 Jul; 24(7):2099-104. PubMed ID: 23247329 [TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates Use and Risk of Subtrochanteric and Diaphyseal Femur Fractures in Korea: Results from the National Claim Registry. Lee YK; Byun DW; Jung SM; Kwon HY; Kim HY; Kim SH; Kim TY; Jang S; Ha YC Calcif Tissue Int; 2019 Mar; 104(3):313-319. PubMed ID: 30446771 [TBL] [Abstract][Full Text] [Related]
36. Long-term benefits and risks of parathyroid hormone treatment in compliant osteoporotic patients. A Danish national register based cohort study. Thorsteinsson AL; Hansen L; Vestergaard P; Eiken P Arch Osteoporos; 2018 May; 13(1):50. PubMed ID: 29717390 [TBL] [Abstract][Full Text] [Related]
37. Bisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysis. Prieto-Alhambra D; Javaid MK; Judge A; Maskell J; Kiran A; Cooper C; Arden NK Osteoporos Int; 2011 May; 22(5):1555-71. PubMed ID: 20694456 [TBL] [Abstract][Full Text] [Related]
38. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Ross S; Samuels E; Gairy K; Iqbal S; Badamgarav E; Siris E Value Health; 2011 Jun; 14(4):571-81. PubMed ID: 21669382 [TBL] [Abstract][Full Text] [Related]
39. Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. Sampalis JS; Adachi JD; Rampakakis E; Vaillancourt J; Karellis A; Kindundu C J Bone Miner Res; 2012 Jan; 27(1):202-10. PubMed ID: 21976304 [TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference. Beard MK Curr Med Res Opin; 2012 Jan; 28(1):141-7. PubMed ID: 22103779 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]